ClinicalTrials.gg

Program

pegvaliase

Also written as “Pegvaliase”, “rAvPAL-PEG” and “BMN165 20mg/day”.

Its studies are mostly in Phenylketonurias, led by BioMarin Pharmaceutical.

Furthest: phase 4, since Mar 13, 202610 company-led studies, 2 open or runningNext primary completion: Sep 30, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BioMarin Pharmaceutical102 open or runningphase 4since Mar 13, 2026Mar 6, 2008Sep 30, 2027phase 4 · NCT07477691

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 6, 2008First study: phase 1 study in PhenylketonuriasFirst studyNCT00634660 · 25 enrolled · United States
  2. Jun 17, 20092 phase 2 studies in PhenylketonuriasNCT00925054, NCT00924703
  3. Sep 29, 2010Phase 2 study in PhenylketonuriasNCT01212744 · 16 enrolled · United States
  4. Mar 5, 2012Phase 2 study in PhenylketonuriasNCT01560286 · 24 enrolled · United States
  5. Mar 18, 2013Phase 3 study in PhenylketonuriasNCT01819727 · 261 enrolled · United States
  6. Jun 18, 2013Phase 3 study in PhenylketonuriasNCT01889862 · 215 enrolled · United States
  7. Sep 4, 2018Phase 3 study in PhenylketonuriasNCT03694353 · 37 enrolled · United States
  8. Feb 1, 2022Phase 3 study in PhenylketonuriasNCT05270837 · 55 enrolled · United States, Germany
  9. Mar 13, 2026Phase 4 study in PhenylketonuriasNCT07477691 · 12 planned · United States

Ahead

  1. Sep 30, 2027Primary completion: phase 4 study in PhenylketonuriasNCT07477691

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07477691Phenylketonurias · United States4RecruitingSep 30, 202712
NCT05270837Phenylketonurias · United States, Germany3Active, not recruitingJan 14, 202555
NCT03694353Phenylketonurias · United States3CompletedJan 13, 202137
NCT01889862Phenylketonurias · United States3CompletedJan 13, 2016215
NCT01819727Phenylketonurias · United States3CompletedNov 25, 2015261
NCT01560286Phenylketonurias · United States2CompletedSep 201324
NCT01212744Phenylketonurias · United States2CompletedApr 201516
NCT00924703Phenylketonurias · United States2CompletedJan 31, 201968
NCT00925054Phenylketonurias · United States2CompletedJun 201540
NCT00634660Phenylketonurias · United States1CompletedApr 200925

How it is read

Names in the registry

  • “Pegvaliase”, 3 entries
  • “rAvPAL-PEG”, 3 entries
  • “BMN165 20mg/day”, 1 entry
  • “BMN165 40mg/day”, 1 entry
  • “BMN 165 (rAvPAL-PEG)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.